| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H21F4NO3S2 |
| Molecular Weight | 499.541 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(CSC2=CC=C(OC(C)(C)C(O)=O)C(C)=C2)SC(=N1)C3=CC=C(C=C3F)C(F)(F)F
InChI
InChIKey=ZUGQWAYOWCBWGM-UHFFFAOYSA-N
InChI=1S/C23H21F4NO3S2/c1-12-9-15(6-8-18(12)31-22(3,4)21(29)30)32-11-19-13(2)28-20(33-19)16-7-5-14(10-17(16)24)23(25,26)27/h5-10H,11H2,1-4H3,(H,29,30)
| Molecular Formula | C23H21F4NO3S2 |
| Molecular Weight | 499.541 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Sodelglitazar is an oral insulin sensitiser, a peroxisome proliferator-activated receptor (PPAR) pan agonist that was under development with GlaxoSmithKline for the treatment of hyperlipidaemia, type 2 diabetes mellitus and metabolic syndrome. Sodelglitazar exerts higher binding affinity for the delta subtype as compared to gamma and alpha subtypes. Sodelglitazar was being investigated in Phase II clinical trials for the treatment of T2DM and its complications, but this research has been discontinued.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
